Q32 Bio (QTTB) Common Equity (2017 - 2026)

Q32 Bio's Common Equity history runs 10 years deep, the most recent figure standing at $46.3 million for Q1 2026.

• In Q1 2026, Common Equity rose 1253.79% year-over-year to $46.3 million; the TTM figure through Mar 2026 stood at $46.3 million (up 1253.79% YoY), while the FY2025 annual figure was $42.0 million, up 640.33% from the prior year.
• Common Equity was $46.3 million for Q1 2026 at Q32 Bio, up from $42.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $266.3 million in Q1 2022 to a low of -$182.9 million in Q4 2023.
• Historically, Common Equity has averaged $7.4 million across 5 years, with a median of $5.7 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Common Equity sank 200.84% in 2025, then surged 1253.79% in 2026.
• A 5-year view of Common Equity shows it stood at -$130.7 million in 2022, then plunged by 39.94% to -$182.9 million in 2023, then surged by 103.1% to $5.7 million in 2024, then soared by 640.33% to $42.0 million in 2025, then advanced by 10.23% to $46.3 million in 2026.
• The last three Common Equity figures came in at $46.3 million (Q1 2026), $42.0 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.